Trial Profile
Proof of Concept Study to Assess Downstream Effects of Using Combined Intranasal Fluticasone Propionate Plus Azelastine Nasal Spray on Asthmatic Inflammation in Patients With Persistent Asthma and Allergic Rhinitis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Azelastine/fluticasone-propionate (Primary)
- Indications Allergic rhinitis; Asthma
- Focus Proof of concept; Therapeutic Use
- Acronyms MAN06
- Sponsors Meda Pharmaceuticals
- 28 Oct 2018 Status changed from recruiting to discontinued.
- 19 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 19 Mar 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.